Fusion of Epstein-Barr virus nuclear antigen-1-derived glycine-alanine repeat to trans-dominant HIV-1 Gag increases inhibitory activities and survival of transduced cells in vivo
- PMID: 18533892
- DOI: 10.1089/hum.2007.095
Fusion of Epstein-Barr virus nuclear antigen-1-derived glycine-alanine repeat to trans-dominant HIV-1 Gag increases inhibitory activities and survival of transduced cells in vivo
Abstract
Trans-dominant human immunodeficiency virus type 1 (HIV-1) Gag derivatives have been shown to efficiently inhibit late steps of HIV-1 replication in vitro by interfering with Gag precursor assembly, thus ranking among the interesting candidates for gene therapy approaches. However, efficient antiviral activities of corresponding transgenes are likely to be counteracted in particular by cell-mediated host immune responses toward the transgene-expressing cells. To decrease this potential immunogenicity, a 24-amino acid Gly-Ala (GA) stretch derived from Epstein-Barr virus nuclear antigen-1 (EBNA1) and known to overcome proteasomal degradation was fused to a trans-dominant Gag variant (sgD1). To determine the capacity of this fusion polypeptide to repress viral replication, PM-1 cells were transduced with sgD1 and GAsgD1 transgenes, using retroviral gene transfer. Challenge of stably transfected permissive cell lines with various viral strains indicated that N-terminal GA fusion even enhanced the inhibitory properties of sgD1. Further studies revealed that the GA stretch increased protein stability by blocking proteasomal degradation of Gag proteins. Immunization of BALB/c mice with a DNA vaccine vector expressing sgD1 induced substantial Gag-specific immune responses that were, however, clearly diminished in the presence of GA. Furthermore, recognition of cells expressing the GA-fused transgene by CD8(+) T cells was drastically reduced, both in vitro and in vivo, resulting in prolonged survival of the transduced cells in recipient mice.
Similar articles
-
Fusion of ubiquitin to HIV gag impairs human monocyte-derived dendritic cell maturation and reduces ability to induce gag T cell responses.PLoS One. 2014 Feb 5;9(2):e88327. doi: 10.1371/journal.pone.0088327. eCollection 2014. PLoS One. 2014. PMID: 24505475 Free PMC article.
-
Self-inhibition of synthesis and antigen presentation by Epstein-Barr virus-encoded EBNA1.Science. 2003 Sep 5;301(5638):1371-4. doi: 10.1126/science.1088902. Science. 2003. PMID: 12958359
-
Targeting of EBNA1 for rapid intracellular degradation overrides the inhibitory effects of the Gly-Ala repeat domain and restores CD8+ T cell recognition.J Biol Chem. 2001 Sep 7;276(36):33353-60. doi: 10.1074/jbc.M104535200. Epub 2001 Jul 2. J Biol Chem. 2001. PMID: 11435434
-
Avoiding proteasomal processing: the case of EBNA1.Curr Top Microbiol Immunol. 2002;269:23-36. doi: 10.1007/978-3-642-59421-2_2. Curr Top Microbiol Immunol. 2002. PMID: 12224511 Review.
-
Justification for the inclusion of Gag in HIV vaccine candidates.Expert Rev Vaccines. 2016 May;15(5):585-98. doi: 10.1586/14760584.2016.1129904. Epub 2015 Dec 28. Expert Rev Vaccines. 2016. PMID: 26645951 Review.
Cited by
-
RNA-based gene therapy for HIV with lentiviral vector-modified CD34(+) cells in patients undergoing transplantation for AIDS-related lymphoma.Sci Transl Med. 2010 Jun 16;2(36):36ra43. doi: 10.1126/scitranslmed.3000931. Sci Transl Med. 2010. PMID: 20555022 Free PMC article. Clinical Trial.
-
Effects of APC De-targeting and GAr modification on the duration of luciferase expression from plasmid DNA delivered to skeletal muscle.Curr Gene Ther. 2015;15(1):3-14. doi: 10.2174/1566523214666141114204943. Curr Gene Ther. 2015. PMID: 25545919 Free PMC article.
-
Stem cell-based approaches to treating HIV infection.Curr Opin HIV AIDS. 2011 Jan;6(1):68-73. doi: 10.1097/COH.0b013e3283412370. Curr Opin HIV AIDS. 2011. PMID: 21242896 Free PMC article. Review.
-
Remodeling of the epitope repertoire of a candidate idiotype vaccine by targeting to lysosomal degradation in dendritic cells.Cancer Immunol Immunother. 2012 Jun;61(6):881-92. doi: 10.1007/s00262-011-1157-5. Epub 2011 Nov 17. Cancer Immunol Immunother. 2012. PMID: 22089857 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials